Trending News on Targeted Oncology, Week of October 2, 2020

Targeted Oncology reviews trending news online for the week of October 2, 2020, including updates in oncology and the latest conference coverage.

October marks both Breast Cancer Awareness Month and Liver Cancer Awareness Month. In recognition of these, Targeted Oncology spoke with 2 experts on the advancements that have been observed in recent years. Ghasson K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, discussed the evolution of treatment options in hepatocellular carcinoma, while Daniel A. Vorobiof, MD, of Belong.Life, discussed the growing role of genomic testing in patients with breast cancer and how this impacts treatment decisions.

Check out the latest conference coverage from the 17th Annual International Society of Gastrointestinal Oncology Meeting.

These updates and others were trending:

FDA Grants Fast Track Designation to Eganelisib Combination in TNBC

A Fast Track designation was granted by the FDA to eganelisib (IPI-549) in combination with an immune checkpoint inhibitor and chemotherapy for the first-line treatment of patients with inoperable locally advanced or metastatic triple-negative breast cancer.

IV Sintilimab and Bevacizumab Biosimilar Improve Survival in Frontline Advanced HCC

The sintilimab injection (Tyvyt) in combination with IBI305 (Byvasda), a biosimilar to bevacizumab (Avastin), improved overall survival as well as progression-free survival compared with sorafenib (Nexavar) as frontline treatment of patients with advanced hepatocellular carcinoma, meeting the predefined primary end point of the phase 3 ORIENT-32 clinical trial.

Phase 3 HERO Study Update Demonstrates Promise for Relugolix in Advanced Prostate Cancer

Relugolix demonstrated a similar rate of castration resistance-free survival compared with the current standard of care leuprolide acetate as treatment of patients with metastatic prostate cancer.

New Drug Application Planned for Submission to FDA for Pacritinib in Myelofibrosis

A New Drug Application for pacritinib is planned to be submitted for potential accelerated approval from the FDA for the treatment of patients with myelofibrosis and severe thrombocytopenia, defined as platelet count less than 50 x 109/L.

2020 ESMO Recap: Oncology Community Unites to Bring Innovation to Patients With Cancer

Several experts in lung cancer, breast cancer, genitourinary cancers, and gastrointestinal cancers spoke with Targeted Oncology on some of the most impactful abstracts from the 2020 ESMO Congress.

Genomic Testing Is Necessary in Non-Small Cell Lung Cancer

Vivek Subbiah, MD, shares his take home message regarding the treatment of patients with non–small cell lung cancer who harbor a RET fusion.

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

In season 1, episode 3 of Targeted Talks, a podcast, 2 experts in breast cancer discussed the treatment landscape and how precision medicine differs in the community versus academic settings.